Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00728910 · ClinicalTrials.gov registry record · Phase 2
Combined Effects of Non-statin Treatments on Apolipoprotein A-I Up-Regulation (CENTAUR): A Feasibility Study
A Phase 2 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT00728910: Completed Phase 2 study, sponsored by University of Pennsylvania.
NCT00728910 is a Phase 2 study that has completed, run by University of Pennsylvania. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00728910, a Phase 2 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
The investigators propose to investigate if using a combination of medications that may improve cholesterol give additional benefit to that gained from the statin medication, Lipitor. It is recommended that patients who meet certain criteria for risk of heart disease take a statin medication to improve cholesterol and hopefully reduce risk of heart disease. The combination therapy will include Lipitor, Niaspan, and investigational medication (known as ABT335) in a class of drugs called fibrates. We are looking to see if and how these three medications together might improve risk factors for atherosclerosis and influence HDL cholesterol. The study will also look at the safety and any side effects that might be associated with this combination of medications.
Interventions
- DRUG Atorvastatin
- DRUG ABT335
- DRUG ER Niacin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2008-06 |
| Est. Completion | 2009-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00728910
The ClinicalTrials.gov registry entry for NCT00728910 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Atorvastatin is the first listed.
NCT00728910 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00728910 about?
NCT00728910 is a clinical study titled "Combined Effects of Non-statin Treatments on Apolipoprotein A-I Up-Regulation (CENTAUR): A Feasibility Study". The investigators propose to investigate if using a combination of medications that may improve cholesterol give additional benefit to that gained from the statin medication, Lipitor. It is recommended that patients who meet certain criteria for risk of heart disease take a statin medication to impr...
What is the current status of trial NCT00728910?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2008-06. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00728910?
The interventions under investigation include: Atorvastatin (DRUG), ABT335 (DRUG), ER Niacin (DRUG).
Who is sponsoring clinical trial NCT00728910?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.